20 reports

  • or Co-development Deals (Part 1), 2017
  • Dermatology Therapeutics Market, Global, Pipeline Products, 2017 (Part 1)

In this context, a first-in-class target is one that is not acted on by any product on the market in any indication across the pharmaceutical industry, and a first-in-class product is one that acts on at least one of these targets.

  • Dermatology
  • Healthcare
  • Pharmaceutical
  • Therapy
  • Galectin Therapeutics Inc.
  • 8.3.2 Deals by Stage of Development and Value
  • Fatty Liver Disease Therapeutics Market, Global, Pipeline Products, 2017 (Part 1)

Of these, only one product - TaiwanJ Pharmaceuticals' JKB-## is in clinical development.

  • Digestive System Disorder
  • Pharmaceutical
  • Therapy
  • Catabasis Pharmaceuticals, Inc.
  • Galectin Therapeutics Inc.
  • RESPIRATORY DISORDERS THERAPEUTICS MARKET, GLOBAL, PIPELINE PRODUCTS, PHASE II, 2017
  • RESPIRATORY DISORDERS THERAPEUTICS MARKET, GLOBAL, PIPELINE PRODUCTS, PRECLINICAL,

DURING CHILDHOOD, ASTHMA IS MORE COMMON IN MALES, WITH A MALE-TO-FEMALE RATIO OF ##:## UP TO PUBERTY, WHEN IT CHANGES TO ##:##.

  • Clinical Trial
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Galectin Therapeutics Inc.
  • Competitive Landscape
  • Of Contents

Dainippon Sumitomo Pharma.

  • Pharmaceutical
  • Europe
  • United States
  • World
  • Galectin Therapeutics Inc.
  • NASH - Phase II-III Pipeline, 2017
  • 9.2.1 Ocaliva (Obeticholic Acid)

INTERCEPT PHARMACEUTICAL' S OCALIVA (OBETICHOLIC ACID) IS ONE OF THE DRUGS LEADING THE LATE-STAGE PIPELINE FOR NASH.

  • Digestive System Disorder
  • Obesity
  • Pharmaceutical
  • Therapy
  • Galectin Therapeutics Inc.
  • Strategic Consolidations
  • Renal Diseases, Global, Pipeline Products, 2017 (Part 3)

In this context, a first-in-class target is one that is not acted on by any product on the market in any indication across the pharmaceutical industry, and a first-in-class product is one that acts on at least one of these targets.

  • Pharmaceutical
  • Renal Disease
  • World
  • Deals & Alliance
  • Galectin Therapeutics Inc.
  • Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details
  • Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Summary Galectin Therapeutics Inc (Galectin Therapeutics), formerly Pro-Pharmaceuticals Inc is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer.The company’s products comprise GR-MD-02 and GM-CT-01. Its GR-MD-02 is a drug candidate used for treating fibrotic...

  • Pharmaceutical
  • Therapy
  • United States
  • Corporate Finance
  • Galectin Therapeutics Inc.
  • Conatus Pharmaceuticals Inc
  • GMCT-01 - Drug Profile

Liver Cirrhosis - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H1 2018, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape. Cirrhosis is scarring of the...

  • Digestive System Disorder
  • Pharmaceutical
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.
  • Conatus Pharmaceuticals Inc
  • Liver Cirrhosis - Pipeline by Galectin Therapeutics Inc, H2 2017

Liver Cirrhosis - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H2 2017, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape. Cirrhosis is scarring of the liver caused by many...

  • Digestive System Disorder
  • Pharmaceutical
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.
  • SEP 14, 2017: G3 PHARMACEUTICALS TO PURSUE A NOVEL CLASS OF CARDIOVASCULAR PHARMACEUTICALS
  • DORMANT PRODUCTS, H2 2017

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H2 2017 Summary Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or...

  • Pharmaceutical
  • United States
  • Litigation And Patent
  • Product Initiative
  • Galectin Therapeutics Inc.
  • CUMBERLAND PHARMACEUTICALS, INC.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2016

Portal Hypertension - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Portal Hypertension - Pipeline Review, H2 2016’, provides an overview of the Portal Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Portal Hypertension, complete...

  • Hypertension
  • Pharmaceutical
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES
  • LIVER FIBROSIS - DORMANT PROJECTS, H1 2017 (CONTD..1), H1 2017

AS OF MARCH ##, 2013, INTERCEPT PHARMACEUTICALS INC OWNED ONE U. S.

  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • Galectin Therapeutics Inc.
  • DORMANT PRODUCTS, H1 2018
  • DORMANT PRODUCTS, H1 2018 (CONTD..1), H1 2018

SEP ##, 2017: G## PHARMACEUTICALS TO PURSUE A NOVEL CLASS OF CARDIOVASCULAR PHARMACEUTICALS G## Pharmaceuticals, a newly formed biopharmaceutical company located in Lexington, MA, announced the start of its research and development program to pursue novel galectin-## inhibito

  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • Galectin Therapeutics Inc.
  • Jan 08, 2016: Galectin Therapeutics Appoints Dr. Marc Rubin Chairman of the Board of Directors
  • Deal Rationale

The drug was well tolerated during this one-year trial.

  • Pharmaceutical
  • Therapy
  • United States
  • Deals & Alliance
  • Galectin Therapeutics Inc.
  • LIVER FIBROSIS - DORMANT PROJECTS, H2 2017 (CONTD..1), H2 2017
  • LIVER FIBROSIS - PIPELINE BY GALECTIN THERAPEUTICS INC, H2 2017

Falk Pharma GmbH (Dr.

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.
  • Deal in brief
  • Deal in brief

Galectin Therapeutics Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline’s Galectin Therapeutics Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions...

  • Healthcare
  • Pharmaceutical
  • Therapy
  • United States
  • Galectin Therapeutics Inc.
  • GMCT-01 - DRUG PROFILE
  • Jan 25, 2018: Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs

Pro-Pharmaceuticals maintain the intellectual property rights to Davanat.

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.
  • GMCT-01 - DRUG PROFILE
  • APR 25, 2017: GALECTIN THERAPEUTICS RECEIVES NOTICE OF JAPANESE DECISION TO GRANT A COMPOSITION OF MATTER PATENT FOR GR-MD-02

Pro-Pharmaceuticals maintain the intellectual property rights to Davanat.

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.
  • GMCT-01 - DRUG PROFILE
  • GLYCOMIMETICS INC

Pro-Pharmaceuticals maintain the intellectual property rights to Davanat.

  • Pharmaceutical
  • Therapy
  • United States
  • Litigation And Patent
  • Galectin Therapeutics Inc.
  • GM-CT-01 - DRUG PROFILE
  • GALECTIN THERAPEUTICS, INC.

(PepTx) is a pharmaceutical company.

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.